跳到正文
原文
Nature 健康护理主题·· 9 天前精选AI 评分70

亚洲多发性骨髓瘤复发/难治患者真实世界治疗模式和临床结局:亚洲多发性骨髓瘤网络研究(AMN010)

Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

AI 导读

该研究通过多中心回顾性分析,评估了亚洲多发性骨髓瘤复发/难治患者在二线、三线和四线治疗中的治疗模式和临床结局,发现治疗模式高度异质性,且随着治疗线数增加,疗效逐渐下降。

推荐理由

研究团队通过多中心回顾性分析,揭示了亚洲多发性骨髓瘤患者治疗模式和临床结局的区域差异,强调了治疗选择的多样性及其对疗效的影响。

正文

To the Editor

Despite significant therapeutic advances, most patients with multiple myeloma (MM) eventually relapse and require successive lines of therapy, with progressively shorter remissions and increasing drug refractoriness [1, 2]. Treatment patterns and outcomes of relapsed/refractory MM (RRMM) patients in Asia differ substantially from those reported in Western populations due to differences in drug availability, reimbursement, healthcare infrastructure, access to clinical trials, patient and carer preferences [3], and potentially disease biology [4]. Despite these important differences, real-world data describing treatment sequencing and outcomes across Asia remain limited. We therefore conducted a multinational and multiregional Asian Myeloma Network (AMN) study to characterize real-world treatment patterns and clinical outcomes in MM patients receiving second line (2 L), third line (3 L), and fourth line (4 L) therapy, to provide a benchmark for RRMM treatment management across Asia.

We performed a multicenter retrospective observational chart review study across six Asian countries and regions, including 1123 patients across 2 L (N = 626), 3 L (N = 341) and 4 L (N = 156), treated between 2020 and 2022 (Supplementary Fig. 1). The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall response rates (ORR), time to next treatment or death (TTNT), overall survival (OS) and prognostic factors associated with outcome. Eligibility criteria, response definitions, and statistical methods are provided in the Supplementary Methods.

Baseline patient characteristics for the combined cohort and individual countries and regions are presented in Suppl. Tables 1–4. The median ages were 64, 63, and 61 years in the 2 L, 3 L, and 4 L cohorts, respectively, with a similar distribution of high-risk disease features.

Treatment patterns were highly heterogeneous across Asia. Overall, 75 unique regimens were identified in 2 L, 79 in 3 L and 52 in 4 L, illustrating the lack of a clearly established standard of care, even in earlier relapse (Table 1). Triplet regimens remained the predominant treatment strategy across all treatment lines, followed by doublets, while the use of monotherapy increased progressively with successive lines of therapy, and was most frequently used in 4 L. Marked regional heterogeneity in treatment patterns was observed (Suppl. Table 5). Mainland China preferentially used triplet- and quadruplet-based regimens across treatment lines, whereas Korea more commonly used doublets in 3 L and monotherapy in 4 L. In contrast, anti-SLAMF7-based regimens were incorporated primarily in Japan. Together, these findings suggest that treatment selection was driven predominantly by differences in access and reimbursement rather than intrinsic biological differences across populations.

Table 1 Summary of treatment regimens in the combined cohort across lines of therapy.

Full size table

Clinical outcomes progressively deteriorated with each successive treatment line (Fig. 1A, B). ORR declined from 71.6% in 2 L to 58.9% in 3 L and 43.6% in 4 L. Similarly, the proportion of patients achieving very good partial response (VGPR) or better declined from 50.3% to 18.0%, while complete response or better (sCR/CR) declined from 23.3% to 5.2% from 2 L to 4 L. Median time to next treatment (TTNT) with advancing therapy lines declined from 26.3 months in 2 L to 15.1 months in 3 L, and median PFS declined from 16.1 months in 2 L to 9.1 months in 3 L and 5.2 months in 4 L. Although the overall pattern of progressively shorter TTNT and PFS with successive therapy was consistent across the region, country-specific differences were observed, including a comparatively prolonged TTNT in the mainland China cohort (Suppl. Table 6), likely reflecting differences in treatment practices and access. Overall, while clinical outcomes varied between participating countries and regions, the progressive deterioration in outcomes with successive lines of therapy was consistently observed across the study population. Country-specific Kaplan-Meier analyses likewise demonstrated geographic variation in both PFS and OS across the 2 L, 3 L, and 4 L settings (Suppl. Figs. 2, 3).

Fig. 1: Progression-free and overall survival according to line of therapy and treatment refractoriness.

A Progression-free survival and (B) Overall survival curves of the combined cohort, stratified by lines of therapy; C Progression-free survival and (D) Overall survival curves of the combined cohort in 4 L, stratified by treatment refractorines.

Increasing drug class refractoriness was strongly associated with inferior outcomes (Fig. 1C, D). Compared with patients who are refractory to none or one drug class, those with double-class refractory disease experienced significantly shorter PFS and OS in 2 L and shorter PFS in 3 L (Suppl. Table 7–9). Outcomes were poorest among patients with triple-class refractory disease in both the combined cohorts and the mainland China cohort. Median PFS for triple-class refractory patients was only 6.1, 8.1, and 3.8 months in the 2 L, 3 L, and 4 L settings, respectively, compared with 12.5, 8.4, and 5.6 months for patients with double-class refractory disease, highlighting the limited efficacy of currently available therapies once multiple drug classes have failed.

To our knowledge, this represents the largest multinational and multiregional retrospective real-world study evaluating treatment patterns and outcomes in RRMM across Asia. Unlike previous reports from individual countries, our study captures the real-word practice across healthcare systems, providing a unique regional perspective on RRMM management.

Several important observations emerge from this study. First, treatment approaches remained highly heterogeneous across treatment lines, reflecting the diversity of healthcare systems, reimbursement models, regulatory approval timelines, and availability of novel therapies across Asia. These factors likely contributed to the marked variation in treatment sequencing observed across the region, with no single treatment strategy predominating even in earlier lines of therapy [5,6,7]. This diversity has important implications for the interpretation of clinical trial data, as variations in prior treatment exposure and sequencing may influence treatment efficacy and the development of drug-class refractoriness, making direct extrapolation of Western real-world evidence to Asian populations challenging. Furthermore, the large number of distinct regimens also precluded robust regimen-specific analyses, and cross-country comparisons should therefore be interpreted with caution.

Second, despite considerable variability in treatment approaches across countries and regions, outcomes declined consistently with each successive therapy line, emphasizing the diminishing efficacy of currently available regimens with advancing relapses. While anti-CD38 antibodies-based quadruplet regimens have been recommended as preferred first-line therapy for both transplant-eligible and transplant-ineligible patients in US and Europe [8], their real-world uptake across Asia during the study period was substantially lower. Limited early exposure to CD38-directed therapy may also explain the relatively stable rates of double-class refractoriness and the steady increase in triple-class refractoriness only in 3 L and 4 L, suggesting continued reliance on existing drug classes in the absence of access to newer therapies.

Third, increasing drug-class refractoriness emerged as a strong predictor of poor outcome, reinforcing that drug-class refractoriness is a more clinically meaningful indicator of disease evolution than treatment line alone and highlighting the importance of introducing effective therapies earlier in the disease course. Despite differences in treatment exposure, outcomes among heavily pretreated patients in our study were comparable to those reported in the LocoMMotion [9] study, with a median PFS of 5.2 months overall (3.8 months in triple-class refractory disease) and median OS of 18.2 months overall (16.6 months in triple-class refractory disease) versus 4.6 and 13.8 months, respectively, in LocoMMotion. Notably, BCMA-directed therapies were not available during our study period, whereas patients in LocoMMotion had access to BCMA-targeted agents such as belantamab mafodotin, that was extensively used in later lines. The similarly poor outcomes despite these differences highlight the substantial unmet need in later-line RRMM and disparities in access to novel immunotherapies across Asia.

The treatment landscape described in this study also reflects an important transition period in Asia. During the study period, incorporation of anti-CD38 monoclonal antibodies varied substantially between countries largely due to reimbursement and access constrains [10, 11], while BCMA-directly therapies were not available. Consequently, this data provides an important baseline against which the impact of CAR T-cell therapy, bispecific antibodies, CELMoDs, and future T-cell-redirecting therapies can be evaluated as they become integrated into routine clinical practice across Asia. Our study also provide baseline data on current treatment and outcomes that may be useful benchmarks for drug approval and reimbursement evaluation in the countries and regions that participated.

This study has several limitations, including its retrospective design, incomplete and missing data for selected variables, particularly cytogenetic abnormalities, and relatively short follow-up. Consequently, overall survival data were immature, with median OS not reached in the 2 L and 3 L cohorts, limiting interpretation of long-term survival outcomes. In addition, the relatively small size of the 4 L cohort should be considered when interpreting subgroup analyses. The median age of our cohort was also younger than that reported in many Western real-world studies, which may reflect differences in population demographics, referral patterns, treatment eligibility, and patient selection across participating centers. Nevertheless, the large multinational and multiregional cohort and representation of real-world clinical practice across diverse healthcare systems provide an important contemporary benchmark for RRMM management in Asia.

In conclusion, this Asian Myeloma Network study provides the largest contemporary real-world management and outcomes of RRMM across Asia, demonstrating regional heterogeneity in treatment patterns together with progressively poorer outcomes with advancing therapy and increasing drug-class refractoriness. The absence of BCMA-directed therapies allows these data to represent a real-world benchmark before widespread adoption of emerging immunotherapies across Asia. Future studies will therefore be able to quantify the real-world impact of these novel therapies against a well-defined historical standard.

Data availability

Upon request. Data may be requested from the corresponding study author.

References

  1. Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022;198:244–56.

    Article  CAS  PubMed  Google Scholar 

  2. Wang PF, Yee CW, Gorsh B, Zichlin ML, Paka P, Bhak RH, et al. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma. 2023;64:398–406.

    Article  CAS  PubMed  Google Scholar 

  3. Tan CJ, Tan MSY, Nagarajan C, Chng WJ, Chee YL, Ooi M, et al. Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma. JCO Oncol Pract. 2023;19:1168–78.

    Article  PubMed  Google Scholar 

  4. Du J, Fu W, Lee JH, Zhang C, Kim K, Liu AJ, et al. IgD myeloma: clinical features and outcome from a multicenter retrospective study in Chinese and Korean of 308 Patients from Asian Myeloma Network (AMN) Project. Blood. 2017;130:5409–5409.

    Google Scholar 

  5. Chng WJ, Nagarajan C, Huang SY, Malhotra P, Hwang YY, Blunk V, et al. A systematic review on the epidemiology and treatment options of multiple myeloma in Asia. Heliyon. 2024;10:e39698.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wu D, Murali B, Clark O, Luan L, Hlavacek P, Chaudhary MA, et al. Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study. Future Oncol. 2026;22:1213–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tachibana Y, Yoon J, Narukawa M. Comparison of Oncology Drug Lag in Japan and South Korea Based on the Interval between the U.S. Approval and the Local Approval. Biol Pharm Bull. 2025;48:11–16.

    Article  CAS  PubMed  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 5.2026. 2026.

  9. Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis). Leukemia. 2024;38:2554–60.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Xu J, Shu M, Chung H, Cui J, Liu Y, Yan W, et al. Two Decades of Real-World Study in Newly Diagnosed Multiple Myeloma: Evolving Treatment and Outcomes in China with Reference to the United States. Cancers (Basel). 2025;18.

  11. Iida S, Yasutomi Y, Samyshkin Y, Chen YC, Chen CC, Lee WS, et al. Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLoS One. 2025;20:e0315932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We acknowledge and thank the patients and their families, participating research teams, the International Myeloma Foundation for study support, and GSK for funding.

Funding

This study was supported by GSK (Study#218521).

Author information

Author notes

  1. These authors contributed equally: Juan Du, Wee Joo Chng.

Authors and Affiliations

  1. Department of Hematology, Singapore General Hospital, Singapore, Singapore

    Melinda SY Tan, Kye Ling Wong & Chandramouli Nagarajan

  2. Department of Hematology, National Cancer Center Singapore, Singapore, Singapore

    Melinda SY Tan, Kye Ling Wong & Chandramouli Nagarajan

  3. National University Cancer Institute of Singapore, Singapore, Singapore

    Cinnie Soekojo & Wee Joo Chng

  4. Singapore Clinical Research Institute, Singapore, Singapore

    Sarah Burkhill & Xinhua Li

  5. Pusan National University Hospital, Busan, South Korea

    Ho-Jin Shin

  6. National Cancer Center, Goyang, South Korea

    Jong Heon Jung

  7. Ewha Womens University Mokdong Hospital, Seoul, South Korea

    Yeung-Chul Mun

  8. Jeonbuk National University Hospital, Jeonju, South Korea

    Ho-Young Yhim

  9. Gachon University Gil Medical Center, Incheon, South Korea

    Jae Hoon Lee

  10. Tan Tock Seng Hospital, Singapore, Singapore

    Ling Cao

  11. Japan Red Cross Medical Center, Tokyo, Japan

    Tadao Ishida

  12. JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan

    Chihiro Shimazaki

  13. Juntendo University Hospital, Bunkyo, Japan

    Makoto Sasaki

  14. Kanazawa University Hospital, Kanazawa, Japan

    Hiroyuki Takamatsu

  15. Nagoya City University Hospital, Nagoya, Japan

    Shinsuke Iida

  16. Shibukawa Medical Center, Shibukawa, Japan

    Hirono Iriuchishima

  17. Tokushima Prefectural Central Hospital, Tokushima, Japan

    Shuji Ozaki

  18. Queen Mary Hospital, Hong Kong University, Hong Kong, Hong Kong

    Karen Tang

  19. National University Taiwan Hospital, Taipei, Taiwan

    Jeffrey Huang

  20. Taichung Veterens General Hospital, Taichung, Taiwan

    Jerry Teng

  21. Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan

    Cheng-Shyong Chang

  22. Seoul Saint Mary’s Hospital, Seoul, South Korea

    Changki Min

  23. Beijing Chaoyang Hospital, Beijing, China

    Wenming Chen

  24. Gunma University School of Medicine, Maebashi, Japan

    Hiroshi Handa

  25. Samsung Medical Center Samsung Medical Center, Seoul, South Korea

    Kihyun Kim

  26. GlaxoSmithKline Pte Ltd, Singapore, Singapore

    Priti Bahety

  27. Shanghai Chang Zheng Hospital, Shanghai, China

    Juan Du

Authors

  1. Melinda SY Tan
  2. Kye Ling Wong
  3. Cinnie Soekojo
  4. Chandramouli Nagarajan
  5. Sarah Burkhill
  6. Xinhua Li
  7. Ho-Jin Shin
  8. Jong Heon Jung
  9. Yeung-Chul Mun
  10. Ho-Young Yhim
  11. Jae Hoon Lee
  12. Ling Cao
  13. Tadao Ishida
  14. Chihiro Shimazaki
  15. Makoto Sasaki
  16. Hiroyuki Takamatsu
  17. Shinsuke Iida
  18. Hirono Iriuchishima
  19. Shuji Ozaki
  20. Karen Tang
  21. Jeffrey Huang
  22. Jerry Teng
  23. Cheng-Shyong Chang
  24. Changki Min
  25. Wenming Chen
  26. Hiroshi Handa
  27. Kihyun Kim
  28. Priti Bahety
  29. Juan Du
  30. Wee Joo Chng

Contributions

MT, KLW, and C Soekojo contributed to data collection, visualization, and writing of the original draft. CWJ contributed to study conceptualization, methodology, writing of the original draft, supervision, and validation. CN contributed to methodology and investigation. SB contributed to software development, data curation, and validation. XL contributed to data curation and investigation. HS, JHJ, YM, HY, JHL, LC, TI, C Shimazaki, MS, HT, SI, HI, SO, KT, JH, JT, CC, CM, WC, HH, KK contributed to data collection and investigation across participating sites. PB contributed to writing–review and editing. CWJ and DJ jointly supervised the study. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Wee Joo Chng.

Ethics declarations

Competing interests

CN: Honorarium: J&J, BMS, IASO, GSK, BeOne, AZ, Roche, Research funding (to institution): J&J, BMS; CWJ: Honorarium: J&J, BMS, Sanofi, Pfizer, IASO, GSK, Research funding: GSK, Sanofi, J&J; PB: employee of GSK and holds financial equities at GSK. The remaining authors declare no competing financial interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, M.S., Wong, K.L., Soekojo, C. et al. Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010). Blood Cancer J. 16, 201 (2026). https://doi.org/10.1038/s41408-026-01641-5

Download citation

  • Received: 06 May 2026

  • Revised: 03 September 2026

  • Accepted: 23 September 2026

  • Published: 11 November 2026

  • Version of record: 11 November 2026

  • DOI: https://doi.org/10.1038/s41408-026-01641-5

来源:Nature 健康护理主题 · nature.com